Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia

Abstract

Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor [corrected] agonist) in subjects with chronic primary insomnia.

Methods: Randomized, multicenter, double-blind, placebo-controlled trial of nightly ramelteon treatment (8 mg or 16 mg) in adults (N=405) with primary chronic insomnia (DSM-IV-TR). Latency to persistent sleep (LPS), TST, sleep efficiency, wake time after sleep onset, and number of awakenings were measured by polysomnography. Subject-reported measures were also assessed.

Results: LPS at Week 1 (primary measure) was significantly shorter with ramelteon 8 mg (32.2 min) or 16 mg (28.9 min) vs placebo (47.9 min; p <0.001). Significant improvements in LPS were maintained at Weeks 3 and 5. TST was significantly longer with both doses of ramelteon at Week 1 (p <0.001) vs placebo. Subject-reported sleep latency was significantly shorter with ramelteon 8 mg at Weeks 1, 3, and 5 (p <0.001) and ramelteon 16 mg at Weeks 1 and 3 (p < or =0.050) vs placebo. Wake time after sleep onset and number of awakenings were not significantly different with ramelteon 8 mg or 16 mg treatment vs placebo. Subjective TST was significantly longer with ramelteon 8 mg at Weeks 1, 3, and 5 (p < or =0.050) and ramelteon 16 mg at Week 1 (p = 0.003) vs placebo. Ramelteon had no clinically meaningful effect on sleep architecture, next-morning psychomotor tasks, alertness, or ability to concentrate. No withdrawal or rebound effects were observed.

Conclusions: Ramelteon reduced LPS over 5 weeks of treatment in subjects with chronic insomnia, with no clinically meaningful sleep architecture alterations, next-morning residual pharmacologic effects, and no evidence of rebound insomnia or withdrawal. No numerical differences were observed between the 2 doses of ramelteon.

Figures

Figure 1

PSG-determined latency to persistent sleep: ramelteon vs placebo treatments. Least-squares mean LPS at Weeks 1, 3, and 5 of double-blind treatment. For comparisons of ramelteon dose and placebo: ***p ≤0.001; **p ≤0.010.

Figure 2

Change from baseline latency to persistent sleep. Least-squares mean change from baseline for PSG LPS at Weeks 1, 3, and 5 of double-blind treatment. For comparisons of ramelteon dose and placebo: ***p ≤0.001; **p ≤0.010.

Figure 3

PSG-determined total sleep time and sleep efficiency: comparison of ramelteon and placebo treatments. Least-squares mean TST and sleep efficiency at Weeks 1, 3, and 5 of double-blind treatment. Sleep efficiency was defined as the TST divided by time-in-bed, multiplied by 100. For comparisons of ramelteon dose and placebo: ***p ≤0.001; *p ≤0.050.